+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review

Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones, and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions, and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East, and North Africa (MENA) and Europe and rest of the world. Hikma Pharmaceuticals is headquartered in London, Greater London, the UK.

Hikma Pharmaceuticals Plc Key Recent Developments

  • Apr 12, 2023: Riad Mishlawi named Chief Executive Officer of Hikma Pharmaceuticals PLC
  • Apr 12, 2023: Hikma Pharmaceuticals Plc Directorate Change
  • Mar 16, 2023: Hikma Pharmaceuticals Announces Annual Report 2022
  • Mar 16, 2023: Hikma Pharmaceuticals Notice of Annual General Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Hikma Pharmaceuticals Plc - Key Facts
  • Hikma Pharmaceuticals Plc - Key Employees
  • Hikma Pharmaceuticals Plc - Key Employee Biographies
  • Hikma Pharmaceuticals Plc - Major Products and Services
  • Hikma Pharmaceuticals Plc - History
  • Hikma Pharmaceuticals Plc - Company Statement
  • Hikma Pharmaceuticals Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Hikma Pharmaceuticals Plc - Business Description
  • Business Segment: Branded
  • Overview
  • Performance
  • Business Segment: Generics
  • Overview
  • Performance
  • Business Segment: Injectables
  • Overview
  • Performance
  • Business Segment: Others
  • Performance
  • Geographical Segment: Europe and Rest of the World
  • Performance
  • Geographical Segment: MENA
  • Performance
  • Geographical Segment: The UK
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Hikma Pharmaceuticals Plc - Corporate Strategy
  • Hikma Pharmaceuticals Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Hikma Pharmaceuticals Plc - Strengths
  • Hikma Pharmaceuticals Plc - Weaknesses
  • Hikma Pharmaceuticals Plc - Opportunities
  • Hikma Pharmaceuticals Plc - Threats
  • Hikma Pharmaceuticals Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Hikma Pharmaceuticals Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 12, 2023: Riad Mishlawi named Chief Executive Officer of Hikma Pharmaceuticals PLC
  • Apr 12, 2023: Hikma Pharmaceuticals Plc Directorate Change
  • Mar 16, 2023: Hikma Pharmaceuticals Announces Annual Report 2022
  • Mar 16, 2023: Hikma Pharmaceuticals Notice of Annual General Meeting
  • Mar 16, 2023: Hikma Pharmaceuticals Plc Annual Financial Report and Notice of AGM
  • Mar 09, 2023: Hikma expands impact in Canada with launches of new sterile injectable medicines
  • Feb 23, 2023: Hikma : Financial Results
  • Oct 13, 2022: Hikma appoints Deneen Vojta, M.D. as a Director
  • Sep 30, 2022: Hikma appoints Victoria Hull and Laura Balan as Directors
  • Aug 04, 2022: Hikma's diversified business delivers resilient H1 performance
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Hikma Pharmaceuticals Plc, Key Facts
  • Hikma Pharmaceuticals Plc, Key Employees
  • Hikma Pharmaceuticals Plc, Key Employee Biographies
  • Hikma Pharmaceuticals Plc, Major Products and Services
  • Hikma Pharmaceuticals Plc, History
  • Hikma Pharmaceuticals Plc, Subsidiaries
  • Hikma Pharmaceuticals Plc, Joint Venture
  • Hikma Pharmaceuticals Plc, Key Competitors
  • Hikma Pharmaceuticals Plc, Ratios based on current share price
  • Hikma Pharmaceuticals Plc, Annual Ratios
  • Hikma Pharmaceuticals Plc, Interim Ratios
  • Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Hikma Pharmaceuticals Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Hikma Pharmaceuticals Plc, Performance Chart (2018 - 2022)
  • Hikma Pharmaceuticals Plc, Ratio Charts
  • Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • F. Hoffmann-La Roche Ltd
  • Advanz Pharma Corp Ltd
  • GSK plc
  • Pfizer Inc
  • Boehringer Ingelheim International GmbH
  • Lannett Co Inc
  • Teva Pharmaceutical Industries Ltd
  • Allergan Ltd
  • Johnson & Johnson
  • Napp Pharmaceuticals Ltd
  • Kyowa Kirin International Plc
  • Bluefish Pharmaceuticals AB
  • Novartis AG
  • Amphastar Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Perrigo Co Plc
  • GSK plc
  • Advanz Pharma Corp Ltd
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Novartis AG
  • Napp Pharmaceuticals Ltd
  • Kyowa Kirin International Plc
  • Johnson & Johnson
  • Allergan Ltd
  • Mallinckrodt Plc
  • Aspen Pharmacare Holdings Ltd
  • Viatris Inc
  • Krka dd Novo Mesto
  • Gedeon Richter Plc
  • Bluefish Pharmaceuticals AB
  • Lannett Co Inc
  • Boehringer Ingelheim International GmbH
  • Adcock Ingram Holdings Ltd